Actinium submits NYSE American compliance plan after equity deficiency notice

Actinium Pharmaceuticals, Inc.

Received NYSE American deficiency notice on May 27, 2026, for Section 1003(a)(ii): equity below required $4M.
Submitted compliance plan on June 18, 2026, outlining intended actions to restore listing standards.
No specific plan details disclosed; exchange will review plan during continued trading.
Company faces potential delisting if plan not accepted or compliance not achieved within extension period.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.